

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Crovalimab for treating paroxysmal nocturnal haemoglobinuria

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

<p>1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?</p>
<p>The following have been identified as potential equality issues during the scoping process:</p> <ul style="list-style-type: none">• Age and pregnancy were highlighted as protected characteristics. Inequalities may arise if different recommendations are made for children and pregnant women. It was noted that there will not be trial data for children and pregnant women at this stage.• All paroxysmal nocturnal haemoglobinuria patients in England can access the two paroxysmal nocturnal haemoglobinuria centres for management of paroxysmal nocturnal haemoglobinuria (Leeds and London).

<p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?</p>
<p>All protected characteristics will be considered by the committee when making its recommendations. However, the committee can only make recommendations within a technology's marketing authorisation.</p> <p>Geographical disparities in access to treatments for paroxysmal nocturnal haemoglobinuria cannot be considered within a technology appraisal.</p>

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Ross Dent

Date: 15/02/2024